Ad Scientiam and Ceres Brain Therapeutics join forces to develop innovative digital biomarkers in Creatine Transporter Deficiency

We are delighted to announce that Ad Scientiam and Ceres Brain Therapeutics are launching a joint research program to develop new digital biomarkers for Creatine Transporter Deficiency syndrome.

Ad Scientiam, a global leader in digital biomarkers, and Ceres Brain Therapeutics, a biotechnology company developing a drug for a rare neurological disease, Creatine Transporter Deficiency syndrome, are joining forces to develop new digital biomarkers aimed at optimizing future clinical trials.